Virility is developing intimate and disposable skin patch. The patch carries an electronic module which generates neuromuscular electrical stimulation. The stimulation is delivered transcutaneously to the adjacent musculature, thus delaying the onset of the premature phase of ejaculation.
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.
Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability
The value of connecting disparate datasets is immense, yet much of this potential remains untapped. Imagine the transformative possibilities: pharmaceutical companies sharing data to design better drugs and evaluate their real-world value, hospitals and HMOs diagnosing rare diseases faster, or financial institutions collaborating to combat financial crime. Rhino Federated Computing makes this vision a reality. Our federated computing platform, powered by advanced edge-computing and federated learning technologies, enables organizations to train and deploy AI models on massive, distributed datasets—without sharing sensitive information or compromising data privacy and sovereignty. This breakthrough approach was pioneered by our co-founder and CEO, Dr. Ittai Dayan, a recognized leader in the field whose work includes a landmark Nature Medicine publication in 2021.
Private Equity Round in 2022
Fu-Gen is an entrepreneurial independent power producer and renewable energy investor.
Mindspace is a boutique flex space provider, presenting a global mindset with a local flavor. We redefine the workplace experience for companies of all sizes. Our beautifully designed spaces, personalized level of service and carefully curated events foster enhanced employee engagement and a strong sense of community, accommodating the way people work, innovate and grow. Our customer base includes blue-chip companies, enterprises and SMBs, in over 40 locations, 20 cities and 7 countries across Europe and the US.
Eleos Health provides automated health tech solutions that accelerate clinicians’ decision-making via an AI-powered Speech-to-Insights system to ensure the provision of personalized and time and cost-effective care.
Lendbuzz develops an AI-based auto finance platform for people with a thin or no credit history. It helps consumers with a thin or no credit history obtain financing when purchasing a car. Powered by machine learning and proprietary algorithms, Lendbuzz is able to better assess the creditworthiness of consumers with limited credit history, who are underserved by traditional banks. By partnering with auto dealerships, Lendbuzz is able to offer consumers attractive financing solutions and dealerships are able to close additional business opportunities and serve a more diversified client base. The company was founded in 2015 and is headquartered in Boston, Massachusetts.
Increasing demands are stressing care managers more than ever before. Imagine if they had a super-powered assistant helping them respond to individuals’ needs with more efficiency and consistency. That’s Laguna Health. Laguna’s AI combines conversational intelligence + clinical protocols—putting Conversational “Care” Intelligence to work for you. With real-time insights our customers deliver better care, faster, using their existing platforms and workflows. No integration is required. It's not just theory: our published clinical research, partnerships with national health plans, and actuarially verified results speak for themselves.
Edocate's platform enables its customers to create unique content in a form of virtual patient cases in a variety of therapeutic areas, to engage healthcare professionals. The platform provides valuable insights into HCP decision-making, clinical gaps and variability in care, prescription patterns, guideline compliance and patient outcomes.
Private Equity Round in 2021
MedMinder Systems provides services that simplify medication management and improve medication adherence. It offers an automatic pill dispenser that reminds users when it is time to take their medication through flashes, beeps, text messages, and phone calls. It also provides the user's caregivers, family members, or pharmacists with notifications about their dosage activity, which can be monitored remotely through a patient profile on MedMinder's website. The company was founded in 2007 and is headquartered in Needham, Massachusetts.
The value of connecting disparate datasets is immense, yet much of this potential remains untapped. Imagine the transformative possibilities: pharmaceutical companies sharing data to design better drugs and evaluate their real-world value, hospitals and HMOs diagnosing rare diseases faster, or financial institutions collaborating to combat financial crime. Rhino Federated Computing makes this vision a reality. Our federated computing platform, powered by advanced edge-computing and federated learning technologies, enables organizations to train and deploy AI models on massive, distributed datasets—without sharing sensitive information or compromising data privacy and sovereignty. This breakthrough approach was pioneered by our co-founder and CEO, Dr. Ittai Dayan, a recognized leader in the field whose work includes a landmark Nature Medicine publication in 2021.
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.
BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy treatments.
Percepto is a developer of autonomous drone technology for inspection and surveillance. The company is at the forefront of redefining how industrial sites and critical infrastructure are holistically inspected and monitored, harnessing remote robotics to autonomously collect, aggregate, and analyze visual data. Leveraging its experience with Percepto Sparrow, the first deployed drone-in-a-box solution on the market, Percepto introduced Percepto AIM (Autonomous Inspection and Monitoring), the first end-to-end autonomous inspection and monitoring platform. Percepto AIM empowers the remote operation center of the future to assess risk, minimize downtime, drive efficiency, increase safety, and reduce operational costs.
Pixellot is a leading sport media company that offers automatic production solutions for the amateur and semi-professional market. Pixellot’s patented technology streamlines the production workflow by deploying an unmanned multi-camera system that covers the entire field. Advanced algorithms enable dynamic coverage of the flow of play and highlight generation. The company streams more than 11,000 live video hours each month to fans, players, and coaches on a variety of platforms. Founded in 2014 by seasoned video and media technology experts, Pixellot has sold over 2,000 systems around the world, deployed with minor leagues, high schools, as well as at youth academies and top league clubs. Pixellot’s partners include ESPN, PlayOn Sports, the US’ biggest high school sports media company and right holder, Sporttotal.tv, Germany’s largest amateur league media platform, global coaching solution provider STATS, SeeUPlay in Mexico and Hockey TV, North America’s largest non-NHL ice hockey streaming platform. The company also works directly with leading clubs such as Bayern Munich, Spain’s Real Sociedad, Dutch AZ Alkmaar and Maccabi Tel-Aviv.
Redpin Therapeutics operates as a preclinical stage gene therapy company. It develops a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system. Its approach integrates powerful principles from synthetic biology, gene therapy, and traditional pharmacotherapy. The company was founded in 2017 and is headquartered in New York.
BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy treatments.
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with a high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-ß, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.
Metabomed designs drugs designed treats cancer. Its drugs target the reprogrammed cancer cell's metabolism to halt their growth, enabling patients to begin their treatment more quickly and result in a higher likelihood of a successful treatment.
Werewolf Therapeutics is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer.
Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and has operated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with a high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-ß, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with a high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-ß, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.
Lendbuzz develops an AI-based auto finance platform for people with a thin or no credit history. It helps consumers with a thin or no credit history obtain financing when purchasing a car. Powered by machine learning and proprietary algorithms, Lendbuzz is able to better assess the creditworthiness of consumers with limited credit history, who are underserved by traditional banks. By partnering with auto dealerships, Lendbuzz is able to offer consumers attractive financing solutions and dealerships are able to close additional business opportunities and serve a more diversified client base. The company was founded in 2015 and is headquartered in Boston, Massachusetts.
ARTSaVIT is a biopharmaceuticals company developing a cancer drug.
Digma Medical is a clinical stage medical device company revolutionizing the treatment of Type-2 Diabetes and other metabolic syndrome disease such as NASH. Founded in 2013 and backed by leading venture capital firms, Digma is dedicated to the development of the DiaGone™ to treat insulin resistance - the underlying mechanism of the disease. The DiaGone™ is an endoscopic, disposable device, that uses state of the art laser technology to treat the duodenum without an implant. The Duodenal Glycemic Control™ procedure is a one-time 30 minute GI procedure, in which the gastroenterologist uses the DiaGone™ to treat the duodenum for restoring the natural ability of the body to control glucose levels, which may provide long term remission from Type-2 Diabetes, NASH, and other metabolic syndrome related disease.
Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded MPM Managing Director Mitch Finer, a well-known biotechnology entrepreneur. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world.
BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy treatments.
Metabomed designs drugs designed treats cancer. Its drugs target the reprogrammed cancer cell's metabolism to halt their growth, enabling patients to begin their treatment more quickly and result in a higher likelihood of a successful treatment.
Sol-Gel designs and delivers innovative dermatological drugs ranging from completely non-leachable to highly-controlled-release of unique formulations and compounds.
Quiet Therapeutics is an emerging biotech company founded in 2010 developing a proprietary nanoparticle-based delivery system (gagomers) focused on oncology and inflammation. Based on the targeting capability of our innovative technology, the company is well positioned to expand the drug target repertoire in cancer and inflammation. The Gagomer delivery approach enables us to target cell components that are not manageable by other therapeutic agents like small molecules or antibodies.
cCAM Biotherapeutics is a pre-clinical stage company developing immunotherapies for cancer. cCAM's lead agent, CM-10, is an immunomodulatory antibody that harnesses the patient's immune system to attack tumors. CM-10 binds CEACAM1, a protein used by cancer cells to suppress the immune system. CM-10 abrogates this effect, leading to a cancer specific immune response in patients.